{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:31:23Z","timestamp":1788089483299,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"DOI":"10.7759\/cureus.101886","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:42:30Z","timestamp":1768902150000},"source":"Crossref","is-referenced-by-count":1,"title":["Multiple Sclerosis With Migraine and Pyoderma Gangrenosum Treated With Ofatumumab and Erenumab"],"prefix":"10.7759","author":[{"given":"Haruhiko","family":"Motegi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104152","article-title":"Multiple sclerosis and migraine: links, management and implications","volume":"68","author":"Mrabet S","year":"2022","unstructured":"Mrabet S, Wafa M, Giovannoni G. Multiple sclerosis and migraine: links, management and implications. Mult Scler Relat Disord. 2022, 68:104152. 10.1016\/j.msard.2022.104152","journal-title":"Mult Scler Relat Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.11477\/mf.1416202363","article-title":"[Therapeutic strategies and disease-modifying therapies for multiple sclerosis] (Article in Japanese)","volume":"75","author":"Motegi H","year":"2023","unstructured":"Motegi H, Kitagawa S, Nakahara J. [Therapeutic strategies and disease-modifying therapies for multiple sclerosis] (Article in Japanese). Brain Nerve. 2023, 75:485-90. 10.11477\/mf.1416202363","journal-title":"Brain Nerve"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al.. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018, 319:1999-2008. 10.1001\/jama.2018.4853","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al.. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018, 38:1026-37. 10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski V","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018, 38:1442-54. 10.1177\/0333102418779543","journal-title":"Cephalalgia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.11477\/mf.1416202361","article-title":"[Migraine medication] (Article in Japanese)","volume":"75","author":"Kikui S","year":"2023","unstructured":"Kikui S, Takeshima T. [Migraine medication] (Article in Japanese). Brain Nerve. 2023, 75:470-8. 10.11477\/mf.1416202361","journal-title":"Brain Nerve"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares L","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, et al.. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:198-211. 10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer RJ","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al.. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018, 378:1277-90. 10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516688955","article-title":"Processing speed test: validation of a self-administered, iPad(\u00ae)-based tool for screening cognitive dysfunction in a clinic setting","volume":"23","author":"Rao SM","year":"2017","unstructured":"Rao SM, Losinski G, Mourany L, et al.. Processing speed test: validation of a self-administered, iPad(\u00ae)-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler. 2017, 23:1929-37. 10.1177\/1352458516688955","journal-title":"Mult Scler"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102425","article-title":"Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015","volume":"45","author":"Fang CW","year":"2020","unstructured":"Fang CW, Wang HP, Chen HM, Lin JW, Lin WS. Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015. Mult Scler Relat Disord. 2020, 45:102425. 10.1016\/j.msard.2020.102425","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25877","article-title":"Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study","volume":"88","author":"Maggi P","year":"2020","unstructured":"Maggi P, Sati P, Nair G, et al.. Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study. Ann Neurol. 2020, 88:1034-42. 10.1002\/ana.25877","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser SL","year":"2023","unstructured":"Hauser SL, Zielman R, Das Gupta A, et al.. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension. Mult Scler. 2023, 29:1452-64. 10.1177\/13524585231195346","journal-title":"Mult Scler"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser SL","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al.. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017, 376:221-34. 10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser SL","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, et al.. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008, 358:676-88. 10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen P","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, et al.. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015, 385:1873-83. 10.1016\/S0140-6736(15)60027-7","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/410742-multiple-sclerosis-with-migraine-and-pyoderma-gangrenosum-treated-with-ofatumumab-and-erenumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:42:31Z","timestamp":1768902151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/410742-multiple-sclerosis-with-migraine-and-pyoderma-gangrenosum-treated-with-ofatumumab-and-erenumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.101886","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}